Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P79Z | ISIN: US00166B1052 | Ticker-Symbol:
NASDAQ
28.03.24
20:37 Uhr
10,890 US-Dollar
-0,520
-4,56 %
1-Jahres-Chart
ALX ONCOLOGY HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ALX ONCOLOGY HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ALX ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.03.Stifel downgrades ALX Oncology to hold, sees evorpacept as fully valued1
08.03.ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer3
08.03.Stifel cuts ALX Oncology stock, sees limited upside for 'evorpacept'2
08.03.ALX ONCOLOGY HOLDINGS INC - S-8, Securities to be offered to employees in employee benefit plans-
08.03.ALX Oncology Holdings Inc reports results for the quarter ended in December - Earnings Summary1
07.03.ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update27SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
► Artikel lesen
07.03.ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report1
05.03.ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting206- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX...
► Artikel lesen
26.12.23ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report2
08.12.23Jefferies raises ALX Oncology to buy, cites upcoming catalysts9
14.11.23The Latest Analyst Ratings for ALX Oncology Holdings5
14.11.23ALX Oncology GAAP EPS of -$1.24 misses by $0.373
14.11.23ALX Oncology Holdings Inc reports results for the quarter ended in September - Earnings Summary2
13.11.23ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update259SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
► Artikel lesen
13.11.23ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report1
10.10.23ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares2
06.10.23ALX Oncology stock rockets 27% after being halted for volatility3
05.10.23Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More42
05.10.23What's Going On With ALX Oncology Stock?5
05.10.23ALX Oncology jumps as share offering priced at no discount3
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1